Stockwinners Market Radar for September 26, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:13 EDT Cathie Wood's ARK Investment bought 1.03M shares of Ginkgo Bioworks today

20:11 EDT Cathie Wood's ARK Investment bought 508K shares of Rocket Lab today

19:10 EDT Privia Health director sells $4.88M in common stock - In a regulatory filing, Privia Health disclosed that is director Jeffrey Butler sold 140K shares of common stock on September 22nd in a total transaction size of $4.88M.

17:30 EDT Lilly USA sued by EEOC over age discrimination - Lilly USA violated federal law by intentionally failing to hire older workers based on their age for pharmaceutical sales representative positions from April 2017 to 2021, the U.S. Equal Employment Opportunity Commission charged in a lawsuit filed Monday. According to the EEOC's suit, in 2017, Lilly's senior vice president for human resources and diversity recognized at a Leadership Town Hall that Lilly's workforce was composed of older workers. The senior vice president then announced goals for "Early Career" hiring to add more millennials to Lilly's workforce. Thereafter, Lilly changed its hiring preferences and intentionally under-hired older candidates for sales representative positions in favor of younger candidates based on their age. Such alleged conduct violates the Age Discrimination in Employment Act which prohibits discrimination against applicants age 40 and over. The EEOC filed suit in the U.S. District Court for the Southern District of Indiana, Indianapolis Division after first attempting to reach a pre-litigation settlement through its conciliation process. The agency seeks back pay and liquidated damages for applicants subjected to unlawful age discrimination. The suit also seeks injunctive relief to prevent and correct age discrimination and training of Lilly's managers and supervisors about federal equal employment opportunity laws.

17:16 EDT L3Harris Technologies awarded $886.53M Army contract - L3 Technologies was awarded an $886.53M cost-plus-fixed-fee contract for sustainment of the Common Data Link satellite communications program. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of September 22, 2032. U.S. Army Contracting Command is the contracting activity.

16:53 EDT Atlis Motor Vehicles approved to trade on Nasdaq - Atlis Motor Vehicles announced that Nasdaq has approved its application to list on Nasdaq Exchange. The company anticipates initiation of trading on the Nasdaq exchange on September 27. Atlis will be traded under the symbol (AMV).

16:33 EDT Southwest COO Mike Van de Ven to step down - Southwest Airlines Mike Van de Ven announced plans to step down from his role as COO at the end of September and from his role as President at the end of December. He will become an Executive Advisor for the company at the start of 2023. With this announcement, CEO Bob Jordan will assume the additional role of President, effective January 1, 2023. The transition paves the way for several other leadership changes, effective October 1, 2022: Andrew Watterson is promoted from executive VP & Chief Commercial Officer to COO. Ryan Green is promoted from senior VP & Chief Marketing Officer to executive VP & Chief Commercial Officer. Linda Rutherford is promoted from executive VP People & Communications & Chief Communications Officer to Chief Administration & Communications Officer.

16:30 EDT H.B. Fuller names Celeste Mastin as new CEO - H.B. Fuller "announced that Celeste Mastin, Executive Vice President and Chief Operating Officer, will succeed Jim Owens as H.B. Fuller's President and Chief Executive Officer, effective December 4, 2022. Upon assuming the role, Mastin will also join the Company's Board of Directors, replacing Owens, who will be retiring."

16:29 EDT Exicure to resume trading at 16:30ET

16:25 EDT Nautilus up 11% after saying will consider potential sale - Shares of Nautilus were up 18c, or 11%, to $1.85 after resuming trading following the company announcing that its board of directors, with the support of management, has launched a comprehensive review of strategic alternatives, which may include a potential sale of the company.

16:23 EDT Nautilus trading resumes

16:22 EDT Ingredion increases quarterly dividend 9% to 71c per share - The board of directors of Ingredion declared a quarterly dividend of 71c per share on the company's common stock, an increase of 9% over the previous quarter's dividend per share. The dividend is payable on October 25 to stockholders of record at the close of business on October 6. This is the eighth consecutive year Ingredion's board approved a quarterly dividend increase in the third quarter.

16:19 EDT Sonoco ThermoSafe, United Cargo enter global lease agreement for Pegasus ULD - Sonoco ThermoSafe and United Cargo announced a global lease agreement for the new Pegasus ULD temperature-controlled bulk shipping container. The agreement enables pharmaceutical freight forwarders access to Pegasus ULD containers directly from United Cargo. Sonoco ThermoSafe's Pegasus ULD is the the first FAA and EASA-approved passive bulk temperature-controlled ULD container for pharmaceutical use, which enables it to speed through international air freight handling and customs processes at the lowest possible cost. With a focus on sustainability, the Pegasus ULD is engineered with composite materials, offering a lighter solution that is also substantially more damage-resistant than traditional metal containers. Additionally, the Pegasus ULD contains a fully integrated, FAA-approved telemetry system providing real-time, cloud-based data on payload and ambient temperature and key environmental factors, precisely synchronized with GPS location. United Cargo has over 90 stations in their TempControl global network, trained on pharmaceutical handling according to IATA Temperature Control Regulations. Passive TempControl shipments receive higher boarding priority and enhanced temperature-controlled storage access.

16:16 EDT Corvus announces partner receives approval for IND application in China - Corvus Pharmaceuticals announced that the IND application to initiate a Phase 1/1b clinical trial of mupadolimab has been approved by the Center for Drug Evaluation of the China National Medical Products Administration. The study will be conducted by Angel Pharmaceuticals, Corvus' partner in China. Mupadolimab is a humanized monoclonal antibody designed to be directed against CD73 with a proposed unique mechanism of activating B cells to generate immune responses to tumor antigens and viruses, in patients with relapsed refractory non-small cell lung cancer, or NSCLC, and head and neck squamous cell cancers, or HNSCC. Corvus co-founded Angel Pharma to develop its pipeline in greater China. Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize mupadolimab in greater China. Corvus has studied mupadolimab in a Phase 1/1b clinical trial, with a focus on expansion cohorts in patients with HNSCC that have failed previous treatment with anti-PD-1 therapy and chemotherapy and relapsed refractory NSCLC who have failed previous treatment with anti-PD(L)-1 therapy and chemotherapy. Based on the results to-date, Corvus believes this program is ready to advance into a randomized Phase 2 clinical trial evaluating mupadolimab in combination with pembrolizumab and chemotherapy as a potential front-line therapy for the treatment of patients with NSCLC. Angel Pharma is examining mupadolimab in a Phase 1/1b clinical trial designed to confirm the dose and evaluate the safety, pharmacokinetics, immune biomarkers, and efficacy as a single agent, and in combination with pembrolizumab. Patients with NSCLC and HNSCC are eligible. The clinical trial's efficacy endpoints are complete response, partial response, disease control rate, duration of response, progression-free survival, and overall survival.

16:15 EDT Redwood Trust names Fred Matera CIO - Redwood Trust announced changes to its leadership team as part of a strategic evolution of its organizational structure. Fred Matera, Redwood's current Head of Residential, will assume the role of Chief Investment Officer of Redwood, overseeing centralized investment, capital markets and distribution functions across the Company's investment portfolio and Business Purpose Lending and Residential Mortgage Banking businesses. In addition, Beth O'Brien, Founder and Chief Executive Officer of CoreVest American Finance Lender LLC, and Christopher Hoeffel, President of CoreVest, will depart from Redwood on October 14, 2022. These departures are scheduled to occur on the third anniversary of Redwood's acquisition of CoreVest as part of a planned transition to a seasoned group of leaders within CoreVest. Dash Robinson, Redwood's President, will continue to maintain oversight over both of Redwood's mortgage banking platforms.

16:10 EDT Dragon Victory receives minimum bid deficiency notice from Nasdaq - Dragon Victory International Limited announced that on September 21, it received written notice from The NASDAQ Stock Market notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's ordinary shares for the 30 consecutive business days from August 9 to September 20, the Company no longer meets the minimum bid price requirement.

16:06 EDT Nautilus announces review of strategic alternatives - Nautilus announced that its Board of Directors, with the support of management, has launched a comprehensive review of strategic alternatives, which may include a potential sale of the Company, to identify opportunities to accelerate the Company's digital transformation under its previously announced North Star plan and enhance shareholder value. The Board has engaged Evercore as a financial advisor to assist in the process. The Board has not set a timetable for the conclusion of this review and there can be no assurance that the review will result in any transaction or other strategic change. Nautilus does not intend to comment regarding developments in the process, unless it determines that further disclosure is appropriate or necessary. "We have made tremendous progress executing our North Star strategy and transforming Nautilus from a product-led hardware company to a consumer-led, digitally connected company," said Anne Saunders, Chairman of the Board. "Given the dynamic market environment and growth of the home fitness sector, as well as the potential we see to accelerate North Star, the Board felt the time was right to review strategic options."

16:03 EDT Exicure to cut workforce by 65%, enters into agreement with investor CBI USA - Exicure "announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value. After a strategic review of the Company's business plans and objectives and its existing cash resources, the Company's Board of Directors has approved the following: A workforce reduction of approximately 66%, expected to be completed by the fourth quarter of 2022; Cessation of all R&D activities, including suspension of all partnered programs; Exploration of divesture opportunities for clinical-stage asset in immuno-oncology and preclinical candidates, including the SCN9A product candidates for neuropathic pain; and Company's executive team is expected to remain in place following the restructuring and realignment. The company estimates that it will incur total expenses relating to the restructuring of approximately $0.5M, consisting of severance and termination-related costs and expects to record a significant portion of these charges in the third quarter of 2022. This restructuring plan is expected to extend the Company's cash runway into Q2 of 2023 based on current operating plans and estimates. For the SCN9A program targeting the Nav 1.7 channel for neuropathic pain, Exicure developed several potential candidates that have shown promising activity in preclinical studies with a significant level of knockdown of the SCN9A mRNA transcript. Unfortunately, results from a recent in-vivo animal study in non-human primates did not meet desired target engagement levels as observed in previous in vitro preclinical studies. Additional preclinical studies would be required to understand recent findings, likely delaying the timing of IND-enabling work. As a result, Exicure has suspended further pre-clinical activities for the SCN9A program as it assesses strategic alternatives for all its assets, including its platform technology, with the goal of maximizing stockholder value. Exicure also announced that it has agreed, subject to customary closing conditions including stockholder approval, to sell an aggregate of 3,400,000 shares of its common stock at a purchase price of $1.60 per share to existing investor, CBI USA, Inc., a subsidiary of CBI, Co. Ltd., in a private placement in public equity ("PIPE") financing. Upon satisfaction of certain closing conditions including approval by Exicure stockholders, CBI USA would hold a controlling position in Exicure equivalent to approximately 50.4% of the total voting power (based on the current number of outstanding shares of common stock). Under the terms of the transaction, assuming stockholders approve the transaction, CBI USA will also receive the right to nominate the number of directors to the Company's Board equivalent to its proportional equity ownership of shares of the Company's common stock from time to time, subject to approval by the Board and compliance with the provisions of applicable securities legislation, regulations, rules, policies and Nasdaq rules including, but not limited to, Nasdaq Listing Rule 5640. Exicure anticipates that the gross proceeds from the PIPE will be approximately $5.4 million, before deducting transaction-related expenses payable by the Company and will be used for working capital and general corporate purposes. The transaction was approved by the Board of Directors of Exicure and Exicure stockholders will receive a proxy statement seeking their approval of the transaction with CBI USA in the coming weeks."

16:00 EDT Exicure Inc trading halted, news pending

15:35 EDT Norfolk Southern issues service update in preparation for Hurricane Ian - Norfolk Southern issued the following service update: "Norfolk Southern is monitoring Hurricane Ian which is forecasted to strengthen as it moves north through the Gulf of Mexico. Its winds are expected to begin impacting the southeast on Wednesday, September 28 before making landfall at the northwest coast of Florida on Friday, September 30. Currently, there are no impacted service areas and Norfolk Southern is operating as scheduled. However, high winds and heavy rains could impact rail operations later this week. Norfolk Southern is positioning generators and equipment in advance of the storm and will provide updates as conditions change. Customers with shipments moving through the southeast and mid-Atlantic should prepare for delays."

15:13 EDT Freeman Capital tweets 'just the beginning' on response to Mind Medicine - Freeman Capital tweeted: "This is just the beginning. Details to come this week. $MNMD" regarding Mind Medicine. Jake Freeman, an applied mathematics and economics major at the University of Southern California who made $110M trading Bed Bath & Beyond (BBBY), built an activist stake, along with his uncle, Dr Scott Freeman, a former pharmaceutical executive, in Mind Medicine, Antoine Gara and Madison Darbyshire of Financial Times reported in August. Reference Link

14:23 EDT PagSeguro sees 'relatively negligible' impact to 2023 net income from resolution - PagSeguro Digital Ltd., or PagBank PagSeguro, announced that it wishes to clarify certain information in light of the release of Resolution 246/2022 issued by the Brazilian Central Bank this morning. "PAGS reinforces the message in its previous press release dated October 15, 2021: the expected impact on PAGS's 2023 net income is relatively negligible, anticipated to be around +1%/-1%, given that the potential cost savings in PAGS's merchant acquiring unit related to the interchange cap on prepaid and debit cards combined with the lower settlement period are expected to offset lower revenues in PAGS's card issuance unit. The company will continue to diversify its portfolio and revenues in PagBank, keeping its emphasis on broad financial inclusion, which began with the payments industry," the company stated. Reference Link

13:34 EDT Assurant announces multiyear extension of T-Mobile device protection partnership - Assurant (AIZ) announced a multiyear extension of its "long-standing partnership" with T-Mobile (TMUS) to continue providing mobile device protection solutions. "Over the last ten years, the two companies have leveraged innovation and agility to enhance the device ownership experience for customers. Initially starting with trade-in and expanding to device protection, the relationship has broadened to offer additional value through upgrade and repair services, premium tech support and on-device diagnostics. Starting in October, T-Mobile's device repair program will be offered at Assurant's nationwide network of nearly 500 Cell Phone Repair by Assurant locations... Assurant expects the impact of these changes, including costs to support the transition from the current in-store setup to CPR locations, to be neutral to operating results in 2022. Over the long term, Assurant expects to continue to benefit from greater scale across the suite of services provided to T-Mobile's customers," the company stated.

12:00 EDT CS Disco falls -10.6% - CS Disco is down -10.6%, or -$1.20 to $10.08.

12:00 EDT SES AI rises 11.3% - SES AI is up 11.3%, or 51c to $4.96.

12:00 EDT AEA-Bridges Impact Corp. rises 15.7% - AEA-Bridges Impact Corp. is up 15.7%, or $1.22 to $9.00.

11:18 EDT GSUN Stock trading resumes

11:13 EDT GSUN Stock trading halted, volatility trading pause

10:38 EDT Killam Apartment REIT confirms no major damage following Hurricane Fiona - Killam Apartment REIT confirmed that employees and residents are safe, no residents are displaced and there is no major damage to its properties from Hurricane Fiona. Killam mainly experienced issues related to cladding at properties in Charlottetown.

10:23 EDT Fosun Pharma, MAIA announce commercialization of 20ml SPSB liquid product - Shanghai Fosun Pharma announced that the 20 ml, Sodium Phenylacetate and Sodium Benzoate liquid product, which is under an exclusive partnership between Fosun Pharma and MAIA Pharmaceuticals, has been recently launched. Fosun Pharma USA has the exclusive commercial rights of this product in the U.S. market. Based upon market feedback, the usage of 50ml SPSB, as prescribed, predominantly in the pediatric setting, is subject to extensive product wastage which is a huge cost to the healthcare system. SBSP is available in 20 ml and 50 ml vial sizes. Currently, only MAIA has the FDA approval for the 20 ml vial size.

10:11 EDT Atlas Air announces long-term ACMI placement with MSC Mediterranean Shipping - Atlas Air Worldwide Holdings (AAWW) announced that its Atlas Air, Inc. subsidiary and MSC Mediterranean Shipping Company SA have entered into an agreement that enables MSC to expand its reach and capacity for its customers. Under the terms of the long-term ACMI agreement, Atlas Air will operate all four of its new and incoming Boeing (BA) 777-200 freighters on a global basis for MSC, with the first delivery being taken in Q4 2022. Atlas' order of these four aircraft was announced in January 2022. The 777-200Fs will provide dedicated airfreight capacity to meet customer demand and will serve as a complementary service to MSC's container shipping solutions, Atlas Air said in a statement.

10:06 EDT Pizza Hut Canada launches pilot of robot delivery service - Pizza Hut Canada is embarking on its latest innovation in the pizza-verse with the launch of its new robot delivery service. The national chain is partnering with Serve Robotics to host a two-week pilot program in Vancouver, B.C. From now until September 30, select Vancouver customers who place an order via the Pizza Hut app may have their favourite menu items delivered directly to their doorstep via robot. Pizza Hut on 1725 Robson Street in Vancouver was selected as the first location for the pilot. Customers selected for robotic delivery will be able to use the Pizza Hut app to track the robot's location as their order approaches and will receive a unique, one-time pin to retrieve their order from the robot's secure compartment.

10:00 EDT KINS Technology Group Inc trading resumes

10:00 EDT CS Disco falls -8.1% - CS Disco is down -8.1%, or -91c to $10.37.

10:00 EDT Las Vegas Sands rises 8.7% - Las Vegas Sands is up 8.7%, or $3.09 to $38.56.

10:00 EDT Mister Car Wash rises 11.0% - Mister Car Wash is up 11.0%, or 94c to $9.57.

09:47 EDT LG Display falls -5.0% - LG Display is down -5.0%, or -23c to $4.36.

09:47 EDT AMTD Digital falls -5.5% - AMTD Digital is down -5.5%, or -$3.48 to $60.11.

09:47 EDT Las Vegas Sands rises 9.9% - Las Vegas Sands is up 9.9%, or $3.52 to $38.99.

09:46 EDT Scotiabank CEO Brian Porter to retire, Scott Thomson named as replacement - Scotiabank announced Brian Porter's decision to retire as President and Chief Executive Officer, effective January 31, 2023. With this announcement, Scotiabank's board has appointed Scott Thomson as CEO of Scotiabank, effective February 1, 2023. Thomson is currently President and CEO of Finning International and has been a member of the Scotiabank board since 2016. Thomson will initially serve as President, effective December 1, 2022, with responsibility for the bank's business lines: Canadian Banking, Global Banking and Markets, Global Wealth Management, and International Banking. To support the transition, Porter will become a Strategic Advisor to Thomson from February 1, 2023 to April 30, 2023.

09:34 EDT AT&T awarded $119M task order to modernize networking for U.S. CBP - AT&T was awarded a task order to modernize the U.S. Customs and Border Protection's voice and data networks to help ensure reliable, high-speed wireline and wireless connectivity among CBP's Federal Law Enforcement Agents nationwide. The task order is valued at $119 million over 11 years if all options are exercised. It was awarded via the General Services Administration's Enterprise Infrastructure Solutions contract.

09:32 EDT Hostess Brands hires Adrian Poretti as Chief Supply Chain Officer - Hostess Brands (TWNK) announced that Adrian Poretti has joined the company as chief supply chain officer, or CSCO, effective immediately. Poretti reports to Andy Callahan, president and CEO of Hostess Brands, and joins the company's leadership team. He succeeds Gary Schmidt, interim CSCO, who had served in this role since January 2022 and will continue to lead the company's operations and engineering teams. Schmidt will report to Poretti. Poretti joins Hostess Brands after nearly 30 years at Kimberly-Clark (KMB), where he most recently served as vice president, Global Supply Chain Capabilities.

09:30 EDT Vinci Partners selected to manage Sustainable Regional Development Fund - Vinci Partners Investments announced that the Ministry of Regional Development has selected Vinci Partners' Infrastructure segment to manage its Sustainable Regional Development fund. The federal government hired BRL TRUST Investimentos jointly with Vinci Partners to manage the Fund's capital through different strategies, such as the structuring of partnerships between public and private players to develop sustainable infrastructure projects in Brazil. To support these projects, our team can establish guarantee instruments that should have commitments from FDIRS and other private players. Lastly, the Fund could also invest in other infrastructure funds focused on sustainable development. The commitment will start at approximately R$750M and we expect that should be activated in Vinci Partners' AUM towards the end of the fourth quarter of 2022. The mandate has a significant potential to grow over the years, considering its pre-determined hard cap to invest up to R$11B, as the team originates investment opportunities combined with additional capital commitments from the Ministry.

09:22 EDT KINS Technology Group Inc trading halted, news pending

09:18 EDT Stellantis builds global network of collaborative projects - Stellantis is collaborating with researchers, scientists and engineers around the world - one of the largest networks of cooperative innovation - to speed the development and implementation of ground-breaking technologies to help the Company deliver the goals of the Dare Forward 2030 strategic plan, including reaching carbon net zero emissions by 2038. With more than three decades working with public institutions, other R&D centers, academies and various stakeholders, Stellantis is capitalizing on that experience by building one of the biggest and widest collaborative ecosystems in the world, which today numbers 164 running projects and over 1,000 different partners involved worldwide. These projects can combine private and public funding, bringing together the expertise of Stellantis' extensive technical community and top-tier institutions with their highly skilled talent, to seek solutions to the most-challenging issues in global mobility. Together, Stellantis and its unprecedented collaborations are building the common roadmap to cutting-edge freedom of mobility. Stellantis teams from Brazil, Canada, France, Germany, Italy, Portugal and Spain are working in cooperation with other stakeholders on common and harmonized goals. Each collaborative, co-funded project can last up to four years. In addition, other Stellantis teams in Brazil, China, India and the United States are proactively involved in pre-competitive research with industry stakeholders, contributing in-kind resources to address technical issues.

09:15 EDT Progress Software apponts YuFan Stephanie Wang to CLO - Progress (PRGS) announced the appointment of YuFan Stephanie Wang to the role of Executive Vice President, Chief Legal Officer and Secretary. In this role, Stephanie will oversee all aspects of Progress' legal, compliance and corporate governance efforts. Prior to joining Progress, Stephanie was with W. P. Carey Inc. (WPC), where she most recently held the role of Senior Vice President and Deputy Chief Legal Officer.

09:14 EDT Fuwei Films announces results of extraordinary general meeting in September - Fuwei Films announced that an Extraordinary General Meeting of Shareholders was held on September 24, 2022, at 10:00 a.m. at Fuwei Films Co., Ltd., No. 387 Dongming Road, Weifang, Shandong, China. Holders of approximately 70.5% of the Company's outstanding shares, as of the record date, August 22, 2022, were present in person or represented by proxy at the EGM and approved all the proposals as set forth in the Company's proxy statement dated August 22, 2022, including, among others, the authorization and approval of the agreement and plan of merger, dated as of July 18, 2022, by and among the Company and BaiJiaYun Limited, and any and all transactions contemplated by the Merger Agreement and the plan of merger. Completion of the Contemplated Transactions is subject to the satisfaction or waiver of the closing conditions set forth in Merger Agreement.

09:12 EDT Pulmatrix announces patient dosing completing for PUR3100 - Pulmatrix announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine, DHE, in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, tolerability and pharmacokinetics of three distinct dose groups of inhaled PUR3100 with intravenous placebo compared to a single dose of IV DHE with inhaled placebo. Twenty-six healthy subjects were enrolled and each of the four groups contained at least six subjects. Ted Raad, Chief Executive Officer of Pulmatrix, noted "We believe that both the convenience and potential efficacy and tolerability profile of an inhaled DHE will allow for significant adoption, particularly among those who cannot obtain relief from current prescription medications. We look forward to advancing PUR3100 to potentially be a best-in-class product for this debilitating disease."

09:11 EDT Safe Bulkers announces sale of one Kamsarmax vessel for $15.84M - Safe Bulkers announced that it has entered into an agreement for the sale of MV Pedhoulas Trader, a 2006 Japanese-built, Kamsarmax class, dry-bulk vessel at a net sale price of $15.84 million and forward delivery date within December 2022.

09:10 EDT Y-mAbs Therapeutics announces regulatory filing for DANYELZA in Brazil - Y-mAbs Therapeutics announced that Adium Pharma has submitted a regulatory filing for DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the Brazilian Health Regulatory Agency, Agencia Nacional de Vigilancia Sanitaria.

09:08 EDT Digital Ally announces over $1M in August subscription orders - Digital Ally announced over $1 million in new subscription orders for the month of August, adding to an already extensive subscription list. The company's subscription program, which offers agencies flexible payment terms, has been very popular as municipalities continue to deal with tight spending budgets.

09:07 EDT WOW! releases inaugural ESG/sustainability report - WOW! Internet, Cable & Phone released its 2022 ESG/Sustainability Report, detailing the company's dedication to environmental stewardship, its ongoing support of communities and its corporate governance guidelines. The report highlights how WOW! incorporates its ESG framework into its relationships with customers, employees and other stakeholders. "At WOW!, we are guided by our values of Respect, Integrity, Spirit of Service and Accountability. These values help us responsibly manage our natural, social and people resources," said Teresa Elder, CEO of WOW!. "In observance of World Environmental Health Day, we are pleased to provide a more formal look into our culture and sustainability initiatives with our inaugural ESG report as we continue to conduct business with the interests of our employees, customers and our planet at the forefront."

09:05 EDT Creatd receives approval to trade on OTCQB market - Creatd announced that it has qualified to trade on the OTCQB Venture Marketplace. The Company has been upgraded to the OTCQB from the Pink market. Creatd begins trading today on the OTCQB under the symbol "CRTD" and investors can find quotes for the Company's common shares on the OTC Markets website. Commented Creatd Chairman and CEO Jeremy Frommer, "With today's announcement we have officially taken our first step in our effort to have Creatd stock reinstated for listing on the Nasdaq, or pursue a larger exchange, the NYSE. Our go-forward plans are underpinned by our view that the distressed levels seen today are a product of market conditions, and not company fundamentals, and the conclusion that to finance properly in a seized capital market would be untenable. Our focus continues to be to generate long-term value for shareholders and to seek an environment, whether that be in the private sector or on an exchange, that accomplishes that goal."

09:04 EDT KAUST selects HP Enterprise to build supercomputer in Middle East - Hewlett Packard Enterprise announced that King Abdullah University of Science and Technology or KAUST selected HPE to build its next-generation supercomputer, Shaheen III, to deliver state-of-the-art supercomputing and artificial intelligence capabilities for advancing research in fields such as food, water, energy and the environment. Supercomputing capacity has become increasingly vital to global innovation, industry competitiveness and economic growth. From accelerating vaccine discovery to fight a pandemic, advancing clean energy systems to increase sustainability, to enabling new possibilities in AI, supercomputing is a core technology to solving the world's most challenging scientific and engineering problems.

09:03 EDT Walmart announces launch of two new experiences in Roblox - Walmart (WMT) is announcing the launch of two new experiences in the metaverse mega-platform, Roblox (RBLX). Called Walmart Land and Walmart's Universe of Play, the spaces offer interactive content and entertainment for customers, bringing to life the Walmart's 'isles' in a virtual world. Walmart Land will bring fashion, style, beauty and entertainment items directly to the global Roblox community of over 52M daily users. The retailer will continue to bring the fun with Walmart's Universe of Play - the ultimate virtual toy destination in Roblox, just in time for those oh-so-real holiday wish lists.

09:02 EDT GoHealth receives $50M strategic investment - GoHealth announced that it has closed a $50M private investment. The funding strategically expands GoHealth's shareholder base, enhances its already strong balance sheet as the Company focuses on driving strong cash flow in the near term, enables further investment in new technologies and strategic initiatives, enhances its multi-payer marketplace, and expands its Encompass platform, a revolutionary technology-driven approach to purchasing Medicare Advantage plans. "We are pleased to receive this investment from two significant partners who are sophisticated investors," said Vijay Kotte, CEO of GoHealth. "As we continue our Encompass-driven business transformation, this additional funding will empower us to deliver higher quality customer-service and enhance the differentiated value we bring to the market. We look forward to strengthening our multi-payer marketplace and further improving our ability to help millions of Medicare beneficiaries understand an ever-growing range of coverage alternatives." Kotte continued, "GoHealth is extending the role of the broker beyond traditional enrollment by driving continuous, high-quality engagement with beneficiaries and aligning incentives around retention. We are going to market in unique ways, and by making health insurance more accessible and easier to understand, GoHealth has established itself as a top choice for insurance advice in the U.S. We look forward to building on our position for the benefit of all our valued stakeholders."

08:54 EDT Engine Gaming's Frankly Media, Scioto Valley Guardian enter partnership - Frankly Media announced a partnership with Scioto Valley Guardian. Through Frankly's premium programmatic advertising services, Frankly developed news and entertainment centric iOS and Android apps for The Guardian in which monetization has commenced for both the developed apps and website.

08:52 EDT Sonnet BioTherapeutics appoints Lori McNeill to board of dirctors - Sonnet BioTherapeutics announced that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the company's Business Advisory Committee, where she will serve as the Chairperson. Lori McNeill has over 20 years' experience in the healthcare industry, 13 of which were at Pfizer that included working as the Chief of Staff of Global Operations in the Integrated Health Business unit. Sonnet's BAC will operate as an external body, guiding the company on strategic matters including external collaborations, communications and connecting with government programs, such as the Cancer Moonshot initiative. The BAC will consist of a senior pharma executive from Pfizer, a former congressman with over eight years' experience on Capitol Hill, a former White House aide, a successful entrepreneur and Sonnet's investor relations team. The role of the committee will be to assist in partnering efforts and to elevate the company's profile in the field of immune oncology through communication and leveraging the current and upcoming corporate milestones.

08:50 EDT 180 Life Sciences says clinical development plans 'remain on track' - 180 Life Sciences released a letter to stockholders from its CEO James Woody, which read in part, "In mid-June, I wrote to update you on the status of our Company and our respective investments. In that letter, I provided an update regarding the Company's clinical development plans, which remained on track then, and continue to remain on track today. As a reminder, 180 Life Sciences was founded on the belief that novel anti-inflammatory biologics that are already approved, such as anti-tumor necrosis factor, or adalimumab, could have the potential to address large unmet needs for a variety of additional indications. Currently, we have an active clinical development program that includes Phase 2a and Phase 2b proof-of-concept data which we believe demonstrates that anti-TNF therapy can prevent the progression of Dupuytren's disease in its early stages, as well as plans for two additional Phase 2 studies, one in frozen shoulder which has recently commenced, and the other in post-operative cognitive delirium, for which we just received grant funding. The POCD grant will allow 180LS to determine if administration of an anti TNF antibody, just prior to surgery, either reduces or eliminates the cognitive delirium often seen following surgery. This will be a randomized controlled clinical trial using Remsima, an anti TNF antibody supplied by Celltrion. We think all three indications share a similar underlying mechanism of being critically dependent on TNF. ..In April, we announced that positive Phase 2b data from our trial in Dupuytren's disease had been published in The Lancet Rheumatology. As discussed in that publication, through extensive research of published medical literature, as well as direct clinical and drug development experience, Dr. Nanchahal, Chairman of the 180LS Clinical Advisory Board , believes that the treatment for Dupuytren's disease is most effective during the early nodular stage of the disease, to prevent the development of cords and progression to finger contractures. Dr. Nanchahal's investigation of anti-TNF therapy in Dupuytren's disease in a small Phase 2a study found, that intranodular injection of 40 milligrams of adalimumab in 0.4 milliliter resulted in down-regulation of the myofibroblasts that are responsible for fibrosis and the formation of the nodule in the early stage of Dupuytren's disease. Based upon the Phase 2a findings, he determined that a rigorous randomized, double-blind, placebo-control Phase 2b was warranted in order to attempt to further demonstrate that repurposing anti-TNF therapy for Dupuytren's disease could be an effective treatment for early-stage disease and prevent progression. Based upon published medical literature, clinical experience and the findings from our Phase 2a study, we believed that a primary endpoint of nodule hardness and a secondary endpoint of nodule size could be effective indicators, or surrogates, of long-term disease progression in the absence of a clinical trial with a 10-year follow-up. The trial met its primary endpoint of nodule hardness and, importantly, also the secondary endpoint of nodule size. These were specified before the clinical trial was performed. The results were statistically significant when compared to placebo. Further there is published information indicating that module size correlates with eventual finger contraction. The significant and persistent reduction in nodule size as seen in the 2B trial would be expected to delay or eliminate the progression to finger contraction. This brings us to where we are today. We have a scheduled meeting during Q4 2022 with the U.K.'s Medicines and Healthcare products Regulatory Agency regarding our Phase 2b data in Dupuytren's disease, based on the initial determination by MHRA that our chosen endpoints need further validation. At this meeting, we plan to submit evidence to the MHRA that supports our chosen endpoints. Once this data is submitted, we expect further discussions with the MHRA, in which they are expected to provide final guidance regarding the regulatory approval pathway of an anti-TNF therapy in early-stage Dupuytren's disease. Knowing that this could take several months, we expect to gain clarity from the MHRA by late first quarter of 2023. We also continue to remain in discussions with potential partners, and/or licensees for our Dupuytren's program. In terms of additional progress, we recently disclosed that the first patient in the preventative frozen shoulder trial, also funded by a National Institute for Health and Care Research grant, had received an injection in the trial. There are five active sites, and we will be observing how quickly patients can be enrolled in this trial to gain information on the potential use of anti-TNF agents to reduce or eliminate the need for surgical intervention in this debilitating disease. For the POCD trial, we are gathering all the regulatory approvals necessary to initiate patient treatment, anticipated by Q1 2023, or earlier...In closing, we continue to work diligently and efficiently to deliver treatment options for one of the largest drivers of disease, inflammation. Our active clinical development program currently consists of three potential indications and our clinical development plans for all ongoing programs remain on track. We believe that the successful execution of our current clinical development plans over the long-term could enhance stockholder value."

08:46 EDT Neuronetics launches upgrades to Neurostar's TrakStar platform - Neuronetics announced upgrades today to the TrakStar platform that will offer all NeuroStar providers a more turnkey patient management experience. The TrakStar upgrade includes a simplified interface to quickly sort and prioritize potential patients with ease. NeuroStar's exclusive PHQ-10 tool, launched in early 2022, generates new patient candidates which are automatically loaded into TrakStar. To streamline the benefits investigation process, the BI results automatically appear in TrakStar and can be converted to a NeuroStar patient with the click of a button. Additional TrakStar advances include reporting updates to highlight patients who have not completed prescribed treatment or who may need re-treatment, a revamped tutorial page, and new clinical outcomes scores which can be automatically e-mailed to patients with customizable templates.

08:43 EDT Paratek Pharmaceuticals to host investor update on NTM - Paratek Pharmaceuticals announces that the company will host an update for investors on the global opportunity for NUZYRA in non-tuberculous mycobacteria on Monday, Oct. 3 from 10:30 a.m. to noon Eastern time. During the webinar, Paratek Chief Executive Officer Evan Loh, M.D., and Chief Development and Regulatory Officer Randy Brenner will provide a corporate overview, update investors on the market opportunity for NTM globally for both M. abscessus and M. avium complex, and summarize key takeaways from the company's ongoing scientific program in NTM, which includes the first randomized, placebo-controlled Phase 2b study being conducted in patients with NTM pulmonary disease caused by M. abscessus.

08:42 EDT LM Funding announces energization of 848 Pro Antminer machines - LM Funding America (LMFA) announced the energization of 848 S19J Pro Antminer Mining Machines at the Core Scientific (CORZ) facility in Calvert City, Kentucky. "We are excited to energize our first machines in my home state of Kentucky," said Bruce Rodgers, Chairman and CEO of LM Funding. "We plan to sell our mined Bitcoin to pay operating expenses and reinvest the balance in the purchase and operation of additional Bitcoin mining machines. Generating Bitcoin revenue marks the successful execution to date of our cryptocurrency mining business strategy and next phase of growth for our Company. We continue to believe all 5,400 machines will be energized and anticipated to be generating approximately 544 petahash on an annualized basis by December 31, 2022." The Company also announced that has also ordered 200 Bitmain S19 XP mining machines that have a hashrate of 140 TH/s and are expected to be delivered between December 2022 and January 2023.

08:40 EDT Faraday Future announces resolution to governance dispute with FF Top - Faraday Future announced a resolution to its governance dispute with FF Top and the execution of definitive agreements for new financing. The company continues to have active discussions with capital providers to fund the production and delivery of the FF 91. The company announced a binding governance agreement with FF Top Holding, which resolves a range of issues concerning governance. The governance agreement includes an agreement for FF Top to withdraw its lawsuit against the FFIE board immediately, changes in FFIE board membership and board size, and certain amendments to Faraday Future's shareholder agreement with FF Top. Adam He has been appointed as a new independent board member and a member of the Nominating and Corporate Governance Committee and Audit Committee.

08:39 EDT Tryp Therapeutics files provisional patent applications for psilocybin, TRP-8803 - Tryp Therapeutics announced the filing of two new provisional patent applications. One patent application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other application, #63/375,305, expands the IP related to the Company's development of TRP-8803. The Company is preparing for a Phase 2a clinical trial in collaboration with the University of Michigan to investigate safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia. The clinical studies are expected to reinforce the positive preclinical results obtained by Tryp in an animal model of nociplastic pain. Once issued, the new patent will provide Tryp with Intellectual Property Protection for fibromyalgia utilizing its psilocybin-based candidates.

08:37 EDT Verizon Connect introduces EV features for Reveal - The company said, "Mobile workforce managers looking to make more informed investment and planning decisions as they consider moving to electric vehicles (EVs) from their gasoline-powered ones will benefit from new enhancements, developed exclusively for EVs, in the Verizon Connect Reveal fleet management platform. For those customers who have already made the leap to EVs, the new updates to Reveal enable customers to easily manage their EVs and gas-powered vehicles, increase uptime by seeing their EVs' charging and battery status information all from one platform, and more. Beginning next month, Verizon Connect Reveal customers in the U.S. and Canada will be able to more effectively support various vehicle types - both gasoline-powered and EVs - in one pane of glass. These enhancements will support all Reveal customers including government, small and medium-sized businesses and large enterprise customers who have any combination of Battery Electric Vehicles, Plug-in Hybrid Electric Vehicles and Internal Combustion Engine vehicles with OBD-II Standard Protocol."

08:36 EDT HUMBL, Great Foods2Go enter strategic technology partnership - HUMBL announced the formation of a strategic technology partnership with Great Foods2Go. Under the terms of the agreement, the two companies will integrate HUMBL's mobile application, search engine and marketplace technologies in support of GF2GO and its sub-brand, 1Delivery. The partnership will utilize the full HUMBL platform including: HUMBL Wallet, HUMBL Pay, HUMBL Search Engine and HUMBL Marketplace technologies. The partnership will focus initially on the San Diego, California cloud kitchen location and be designed to expand across multiple locations. The location currently prepares and delivers over 2,000 food orders per month across 30 virtual brands, ranging in popular cuisine styles such as American, Mexican, Italian and more. The companies will use this location as the first "HUMBL Hub" to determine the best technology mix of mobile payment applications, point-of-sale systems, search engine advertising and marketplace delivery technologies. HUMBL and GF2GO will also test virtual brands using HUMBL's mascot, a Bored Ape Yacht Club NFT named "BLUE," using such kitchen themes as "Blue's Tacos" and "Blue's Boring Breakfast," for which HUMBL will receive a revenue share on all orders.

08:36 EDT Powerbridge announces successful launch of its soccer collectable NFTs - Powerbridge Technologies (PBTS) announced that the Company has obtained an exclusive right in China through a partnership with the World Football Collection to offer a series of soccer collectable NFTs on Ali Auction. The soccer collectable NFTs had been launched on Ali Auction since September 20, 2020 with an accumulated views of over 240,000 from potential participants. The first batch of the NFTs were sold out within the first hour of the auction. Ali Auction established by Alibaba Group (BABA), is one of the leading online auction marketplaces with more than 2,000,000 daily active users. Ali Auction connects and benefits from the largest e-commerce platform in China with more than 100 million users. Stewart Lor, CEO of Powerbridge commented: "I am thrilled that we have successfully launched our NFTs on Ali Auction. We will continue to strive and expand our new business in metaverse applications and NFTs, and we anticipate continuous growth from our new business."

08:34 EDT Verizon's response team ready for Tropical Storm Ian - The company said, "As Tropical Storm Ian makes its way towards the US, Verizon's response team is readying to keep communities and first responders connected when it matters most. Teams of Verizon engineers have been actively preparing by running emergency drills, testing fiber and cell site readiness, and ensuring recovery equipment is in place from the tip of Florida, through the Gulf Coast and up the East Coast. Verizon Frontline and the Verizon Frontline Crisis Response Team also stand ready to provide first responders on the front lines of response efforts with the mission-critical communications support they need."

08:34 EDT Corphousing acquires long-term rights to the Lafayette Hotel in New Orleans - CorpHousing Group announced it has acquired long-term rights to the Lafayette Hotel, a 60-unit historic boutique property located in New Orleans, LA, via a 15-year Master Lease Agreement . The Lafayette Hotel is CHG's first property in New Orleans, joining the Company's portfolio properties in New York, Washington, DC, Miami, Denver, Boston, and Seattle. CHG will manage and market the Lafayette Hotel to business and vacation travelers under its LuxUrbanTM brand, with operations expected to commence in October 2022. The addition of the Lafayette brings to 10 the total number of hotels in CHG's portfolio and the 60 units added under this MLA increases CHG's total units under long-term lease to 1037. The Lafayette Hotel is located on the fashionable St. Charles Avenue Streetcar Line, within the heart of the Historical Arts and Warehouse Districts in the Central

08:33 EDT Profound Medical presents four year follow-up data from TACT trial - Profound Medical announced that updated results from the TACT pivotal study were presented for the first time this past weekend, on Saturday, September 24, 2022, by Laurence Klotz, M.D., FRCSC, CM, Professor of Surgery, University of Toronto and Sunnybrook Chair of Prostate Cancer Research, at the FOCAL 2022 Conference held in Los Angeles, CA. TACT, a prospective, open-label, single-arm pivotal clinical study of whole-gland ablation, enrolled 115 patients with biopsy-proven, organ-confined prostate cancer, with the majority having intermediate risk disease. TACT demonstrated that the TULSA-PRO provides safe and effective prostate tissue ablation, with minimal adverse events, significant prostate volume and prostate-specific antigen reduction, and low rates of residual prostate disease. The study was used to support Profound's application to the U.S. Food and Drug Administration for 510(k) clearance to market TULSA-PRO in the United States, which was granted by the Agency in August 2019. In the presentation entitled "MRI-Guided Transurethral Ultrasound Ablation: Not Just Another Focal Therapy," Dr. Klotz reported that four-year follow-up data from the TACT clinical study continue to demonstrate durable and stable safety and efficacy outcomes. The primary efficacy endpoint of TACT was PSA reduction at one year, which decreased 95% to a nadir of 0.34 ng/ml from a median pre-treatment baseline value of 6.3 ng/ml. By four years, the median PSA nadir further reduced to 0.28 ng/ml. PSA reduction was durable over the extended follow-up period, from 0.53 ng/ml at one year to 0.86 ng/ml at four years. The primary safety endpoint of TACT was the frequency and severity of adverse events graded according to the Common Terminology Criteria for Adverse Events. Following treatment with TULSA-PRO, there were no Grade 4 or higher adverse events, no rectal fistula or injury, and no intraprocedural complications. With four-year follow-up, there were no new device or treatment related adverse events. Secondary oncological endpoints included progression to additional treatment for prostate cancer. At four years, 16% of patients in TACT underwent additional intervention for prostate cancer. Of those that progressed to additional treatment, the majority underwent either salvage radical prostatectomy or salvage external beam radiation therapy, noting that a repeat TULSA procedure was not permitted by protocol. Additional secondary endpoints of TACT focussed on functional side effects commonly associated with current prostate cancer therapies, including erectile and urinary functions. Over the four-year follow-up period, no patient experienced severe erectile dysfunction, and 87% of previously potent patients reported erection firmness sufficient for penetration, demonstrating continued improvement from 75% at one year. Urinary function was durable over the four-year follow-up period, with 99% of patients preserving urinary continence and 94% remaining completely pad-free. Lower urinary tract symptoms were stable, with median International Prostate Symptom Score improving from 7 at pre-treatment baseline to 5 at four years. In addition to the TACT study, Dr. Klotz's presentation reviewed additional post-market clinical publications of TULSA-PRO, including focal, partial-gland and customized ablation of localized prostate cancer, salvage TULSA of radio-recurrent prostate cancer, and relief of LUTS due to benign prostatic hyperplasia. A systematic review of the TULSA procedure published by Dora et al in the Journal of Endourology earlier this year was also highlighted, noting that potency preservation and freedom from salvage treatment were associated with the extent of the planned ablation fraction, where an ablation plan covering 75-85% of the prostate volume offers an attractive risk-benefit to the patient. Finally, an overview was provided of the ongoing post-market company-sponsored CAPTAIN randomized clinical trial, to which Dr. Klotz is one of the investigators, noting that this is the first Level I study ever conducted comparing an emerging technology directly with radical prostatectomy in men with prostate cancer.

08:28 EDT eFfector Therapeutics appoints Mayank Gandhi as CBO - eFFECTOR Therapeutics announced it has appointed Mayank Gandhi, M.D., as chief business officer. Dr. Gandhi will lead eFFECTOR's corporate growth strategy, business development and partnership opportunities. Gandhi has over 15 years of biopharmaceutical industry and capital markets experience, most recently serving as the vice president of corporate development & strategy of Jiya Acquisition Group.

08:28 EDT Bionano Genomics to provide genetic counseling with OptraHEALTH's HealthFAX - Bionano Laboratories and OptraHEALTH announced their collaboration to utilize HealthFAX's proprietary AI platform to enhance genetic counseling services and improve care for patients receiving diagnostic services through the Bionano Laboratories. Bionano Laboratories utilizes cutting-edge technologies to provide genetic diagnostics in both clinical and research settings. Bionano Laboratories intends to scale its operations while continuing to improve the customer testing experience by adopting the HealthFAX platform. Within Bionano Laboratories' new operational workflow, patients seeking additional information surrounding genetic disorders and testing services are sent a link to a custom HealthFAX virtual assistant through the program's ExpertConnect feature. This feature provides information to patients on the genetic testing process and testing options and collects personal and family history needed for future potential discussions with genetic counselors. The approach will allow Bionano Laboratories to automate parts of their up-front education workflows and reduce the workload for their team, enabling Bionano Laboratories to potentially service greater numbers of patients while providing more efficient and effective customer care to their patients.

08:26 EDT Windtree Therapeutics to present data from Phase 2 study of istaroxime - Windtree Therapeutics reported that a late breaking abstract describing dose response data from its positive Phase 2 clinical study of istaroxime in early cardiogenic shock will be presented on October 2 at the Heart Failure Society of America Annual Scientific Meeting in Washington, DC. The SEISMiC study met its primary endpoint of significantly improved systolic blood pressure over the first 6 hours of study drug infusion. This is an important clinical objective in treating patients with cardiogenic shock. The significant improvement in blood pressure profile persisted through 24 hours. Patients treated with istaroxime experienced a substantial increase in stroke volume that contributed to an increased cardiac output without increasing heart rate. The study met several other secondary endpoint assessments of cardiac function. Importantly, renal function was not worsened with istaroxime infusion.

08:24 EDT Gain Therapeutics presents preclinical data on GT-02287 - Gain Therapeutics announced the presentation of new preclinical data evaluating one of its lead Structurally Targeted Allosteric Regulator compounds, GT-02287, for the treatment of Parkinson's Disease. Study results were presented at the Shaare Zedek Medical Center GBA Parkinson's disease symposium by Manolo Bellotto, Ph.D., Chief Strategy Officer & General Manager for Gain Therapeutics, in a presentation entitled, "Non-inhibitory Chaperones for GBA-Parkinson's Disease." The study was conducted using human induced pluripotent stem cells derived from donor patients with GBA-associated Parkinson's disease, which were then differentiated into dopaminergic neurons. This "Disease in a dish" model is a cutting-edge research strategy used to model diseases outside the human body. In this study, GT-02287, the Company's lead compound in its Parkinson's program, demonstrated statistically significant, positive effects across a range of measurable parameters, including an increase in GCase levels and lysosomal transport measured by GCase co-localization into the lysosomes. It also reduced pathologically elevated levels of phosphorylated and aggregated alpha-synuclein, which are known to be a critical marker of Parkinson's-induced neurodegeneration. The accumulating preclinical data for GT-02287 demonstrate that Gain's orally bioavailable, brain penetrant small molecule candidate stabilizes and restores the function of misfolded GCase, thus correcting a prominent enzymatic dysfunction underlying GBA1 Parkinson's disease pathology. Approximately 14% of Parkinson's disease patients are known to possess a mutation in the GBA1 gene, which encodes for the lysosomal enzyme GCase, and represents the most common genetic risk factor for Parkinson's disease. GBA1 genetic mutations are associated with earlier onset disease and more aggressive disease progression. Gain believes that GT-02287, with its ability to restore GCase enzyme function, may be able to protect against, or possibly reverse, the damaging cascade of neuronal degeneration implicated in serious CNS disorders like Parkinson's disease.

08:23 EDT PNC Financial announces acquisition of Linga - The PNC Financial Services Group announced it has acquired Linga, a point of sale, POS, and payments solutions firm providing an industry-leading, cloud-based restaurant operating system. The acquisition of Linga and its technology will further expand PNC's digital resources and enhance the bank's capabilities to better serve its hospitality and restaurant industry clients. "We believe this is an exciting opportunity to continue to grow our business and support our existing channel partners and clients, and to do so with a company that shares our vision of delivering innovative and high-quality solutions," said Onur Haytac, founder and CEO of Linga. "As we've worked with PNC over the last several years, we've had incredible success with our combined payments capabilities and we look forward to continuing this strategic collaboration as we move forward together." Linga will retain its founder and CEO, Onur Haytac, its existing management team, and U.S. and Canada-based employees, and will continue to operate out of Naples, Fla., and Toronto. Linga will continue to manage its portfolio of channel partners and clients.

08:21 EDT Jasper announces clinical data from invesigator sponsored study of JSP191 - Jasper Therapeutics announced that data from the company's investigator-sponsored study of JSP191 as a conditioning agent in the treatment of Fanconi Anemia were presented at the annual conference of the Inborn Errors Working Party, a research group of the European Society of Blood and Marrow Transplantation, held on September 23-25, 2022, in Paris, France. The study is a Phase 1/2 clinical trial utilizing JSP191 to treat Fanconi Anemia patients in bone marrow failure requiring allogeneic transplant with non-sibling donors. The objective of the study is to develop cell therapy for Fanconi Anemia which enables enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting TCR ab+ T-cell/CD19+ B-cell depleted stem cells from a donor, after using JSP191 as a part of conditioning. Primary outcome measures include the number of patients without treatment-emergent adverse events following the administration of JSP191. In the data series presented, 100% complete donor chimerism was achieved through six months for the first patient and at one month for the second patient. Neutrophil engraftment was reached on day 11 for both patients and platelet engraftment was achieved on days 9 and 14. JSP191 was cleared by day 9 after dosing and no treatment-related adverse events or toxicities were observed.

08:19 EDT 4Front Ventures launches premier California cannabis brand - 4Front Ventures announced the launch of its premier California cannabis brand, Island Cannabis, in Massachusetts. Following the Company's acquisition in April 2022 of Island, a California-based producer of pre-rolls, flower and concentrate products, the Company began cultivating 11 new Island flower strains at its state-of-art flower facilities located in Holliston, Georgetown and Worcester, Massachusetts. "After our acquisition of Island earlier this year, we quickly set out to strategically bring the very best the brand had to offer to our customers - and I couldn't be more pleased with how quickly and efficiently our team was able to deliver these popular California fan favorites to Massachusetts consumers," said 4Front CEO Leo Gontmakher. "With the launch of Island in the Bay State, we're confident that even the pickiest of cannabis connoisseurs will fall in love with these strains, and that as a whole, the brand will create a loyal following - just as it has in the Golden State. We also look forward to bringing additional high-quality flower products from Island to Massachusetts in the very near future, including larger format flower offerings, and Island's best-selling prerolls and infused prerolls in singles and multipacks."

08:19 EDT MoonLake to initiate global Phase 2 study of Nanobody sonelokimab - MoonLake Immunotherapeutics announced U.S. Food and Drug Administration clearance for a Phase 2 clinical study of the nanobody sonelokimab in patients with active psoriatic arthritis. This is a global clinical study that also includes several European countries. This new study is subsequent to the completion of a global Phase 2b study in moderate-to-severe psoriasis and the initiation of the Phase 2 "MIRA" study in moderate-to-severe hidradenitis suppurativa. The global, randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of different doses of sonelokimab compared to placebo, with adalimumab as an active reference arm, in approximately 200 patients with active PsA. The primary endpoint of the study is the American College of Rheumatology 50 response defined as the percentage of participants achieving greater than or equal to50% improvement in signs and symptoms of disease from baseline, compared to placebo. This study is the first in PsA to use the Nanobody. The study will also include a range of secondary endpoints reflecting the heterogeneous and multi-faceted nature of the disease, including the assessment of skin clearance. disability, enthesitis, pain, as well as other levels of ACR response. Patient enrollment is expected to begin in 2022, with the first sites being initiated in Europe and in the United States. Sonelokimab is an investigational Nanobody designed to treat inflammatory disease by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. In addition, sonelokimab is designed to directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues.

08:19 EDT Rackspace Technology names Amar Maletira as CEO, effective immediately - Rackspace Technology (RXT) announced the appointment of Amar Maletira as CEO. Maletira, who has served as Rackspace Technology's President and CFO since November 2020, has assumed responsibilities effective immediately. David Sambur, Co-Head of Private Equity at Apollo Global Management (APO) and Chairman of the Rackspace Technology Board of Directors, stated, "Amar brings broad management and leadership experience, and over the course of his career, he has helped transform several multi-billion-dollar technology businesses. He has also been instrumental in crafting Rackspace Technology's new strategic direction and operating model. We believe his appointment as CEO will allow us to improve and accelerate the execution of our new go-forward strategy." In addition to the CEO role, Maletira will continue as the CFO until a permanent CFO is named. The company will launch an immediate search for a permanent CFO. Outgoing CEO Kevin Jones will take on the role of operating advisor with Apollo.

08:17 EDT Grom Social's Curiosity Ink Media signs Chelsea, Matt Giegerich to pen story - Curiosity Ink Media announced that it has secured the husband-wife writing team and best-selling authors, Chelsea and Matt Giegerich, to pen the storyline for The Pirate Princess, an original, heartwarming coming-of-age tale about a fearless teenager raised by a notorious, but loving band of pirates

08:16 EDT Jiuzi Holdings launches new corporate website - Jiuzi announced that it has launched a new corporate website. The new website was created to strengthen communication and branding with investors, customers, and business partners. The new site provides key information on JZXN including corporate and product information, corporate news, and important investor information such as access to SEC filings, corporate governance, press releases, and financial reports. "We are pleased to launch our new corporate website, which will significantly enhance communication with the public, improve the visibility of our company in the U.S. marketplace and reinforce our commitment to transparency as a U.S. publicly traded company," commented Shuibo Zhang, CEO of Jiuzi Holdings.

08:15 EDT Connexa Sports receives non-compliance notification from Nasdaq - Connexa Sports Technologies announced that it had received a letter from The Nasdaq Stock Market on September 22, 2022, notifying the Company that it is not in compliance with the periodic filing requirements for continued listing because the Company's Form 10-Q for the period ended July 31, 2022 and Form 10-K for the fiscal year ended April 30, 2022 were not filed with the Securities and Exchange Commission by the required due dates. As previously disclosed, the Company received a letter from Nasdaq on August 16, 2022 regarding the Company not filing its 2022 10-K. The Notice Letter has no immediate effect on the listing or trading of the Company's shares. Nasdaq has provided the Company with 60 calendar days from the date the First Letter was received, until October 17, 2022, to submit a plan to regain compliance with regard to the Periodic Reports. If Nasdaq accepts the Company's plan, then Nasdaq may grant the Company up to 180 days from the prescribed due date for the filing of the 2022 10-K, or February 13, 2023, to regain compliance. The Company expects and intends to submit to Nasdaq the compliance plan with regard to the Periodic Reports by or before October 17, 2022. The Company continues to work diligently to complete its 2022 10-K and targets filing both the 2022 10-K and the 2023 Q1 10-Q in November 2022, after which the Company anticipates regaining and maintaining compliance with its SEC reporting obligations and Nasdaq listing requirements. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

08:13 EDT Enzo Biochem launches AMPIVIEW gene expression platform - Enzo Biochem announced the launch of the AMPIVIEW line, a breakthrough RNA gene expression platform powered by Enzo's LoopRNA in situ hybridization technology. The AMPIVIEW platform with its first products for HPV detection and analysis significantly expands Enzo's position in the oncology market and paves the way for expansion into the growing spatial biology space. The company said, "Enzo's AMPIVIEW RNA products combine the precision of targeted, sequence-specific probes with the superior sensitivity of its novel LoopRNA ISH technology. This innovative design enables sensitive and specific detection of target genes in tissue or cell samples while preserving the morphology. The study of single cells within their native tissue environment, known as spatial biology, helps scientists better characterize and understand disease."

08:12 EDT UMH Properties completes addition of two tranches to Fannie Mae credit facility - UMH Properties announced that it recently completed the addition of two tranches to its Fannie Mae credit facility through Wells Fargo Bank, N.A., for total proceeds of approximately $34 million. One tranche consists of four communities and the other tranche consists of approximately 250 homes located in those communities. Both tranches have a loan term of 10 years with the Community Tranche amortizing over 30 years and the Home Tranche amortizing over 17 years. Interest is at a fixed rate of 5.24%. The proceeds will be used to invest in additional acquisitions, expansions, rental homes and other general corporate purposes, further enhancing our ability to increase shareholder value and provide quality affordable housing in the markets that we serve.

08:11 EDT Phathom Pharmaceuticals appoints James Topper to board of directors - Phathom Pharmaceuticals (PHAT) announced the appointment of James "Jamie" Topper, M.D., Ph.D., to its Board of Directors. Dr. Topper currently serves as a Managing Partner at Frazier Life Sciences, which invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. He is also the Chairman and CEO of Frazier Lifesciences Acquisition Corporation (FLAC).

08:09 EDT Jamf Holding to acquire ZecOps, terms not disclosed - Jamf announced it signed a definitive agreement to acquire ZecOps, Inc. a leader in mobile detection and response. This acquisition uniquely positions Jamf to help IT and security teams strengthen their organization's mobile security posture, accelerating mobile security investigations from weeks to minutes, leverage known indicators of compromise at-scale, and identify sophisticated 0 or 1 click attacks on a much deeper scale. ZecOps will bring important capabilities to the Jamf platform to help address the growing trend of targeted mobile attacks. Jamf offers robust management and mobile security capabilities for iOS devices; however, access to deeper insights into potential security exploits is technically challenging and requires physical access to the device, which is difficult in a remote work environment. ZecOps is a robust, unparalleled solution that provides the deepest layer of insight and assurance for security-conscious customers with high value targets that need something more. ZecOps provides the same level of visibility currently available for macOS through Jamf Protect but for iOS, making it capable of detecting the kinds of sophisticated mobile threats that Apple's Lockdown mode aims to prevent. With ZecOps, users can have both Lockdown mode and ZecOps software operating at the same time. This transaction is subject to the satisfaction of customary closing conditions and is expected to close in the fourth quarter. Terms of the transaction were not disclosed.

08:08 EDT NioCorp, GX announce combination approved by directors, additional details - NioCorp Developments (NIOBF) and GX Acquisition Corp. II (GXII) announced the signing of a definitive agreement for a proposed business combination between the two companies. The Business Combination Agreement has been approved by the Board of Directors of each of NioCorp and GXII. Each of the Board of Directors of NioCorp and the Board of Directors of GXII recommends that NioCorp shareholders and GX stockholders, respectively, vote in favor of the business combination. GenCap Mining Advisory has provided a fairness opinion to the Board of Directors of NioCorp stating that, as of the date of such opinion, and based upon and subject to the assumptions, limitations, and qualifications stated in such opinion, the Transaction, defined below, is fair from a financial point of view to NioCorp shareholders. Scalar has provided a fairness opinion to the Board of Directors of GXII stating that, as of the date of such opinion, and based upon and subject to the assumptions, limitations and qualifications stated in such opinion, the consideration to be received by the holders of GXII's Class A common stock is fair from a financial point of view to such shareholders. THE NIOCORP-GXII BUSINESS COMBINATION AGREEMENT: Under the terms of the Business Combination Agreement with GXII, GXII will merge with and into a wholly owned subsidiary of NioCorp, with GXII surviving the merger as a subsidiary of NioCorp. NioCorp, as the parent company of the merged entity, will issue common shares to the public shareholders of GXII, with the sponsor shareholders receiving shares in GXII that are exchangeable into common shares of NioCorp. The proposed business combination is expected to close in the first quarter of 2023, subject to effectiveness of the registration statement on Form S-4 that NioCorp expects to file, the satisfaction of customary closing conditions, including certain governmental approvals, the approval of the TSX, and the approval of certain elements of the proposed Transaction by a majority of shareholders of GXII and a majority of NioCorp shareholders voting to approve such elements. The proposed additional financings will also be subject to the approval of the TSX. Post-closing, the NioCorp Board will include two directors from GXII. Additional information may be found in the Current Reports on Form 8-K being filed by NioCorp and GXII with the U.S. Securities and Exchange Commission and the applicable Canadian securities regulatory authorities in connection with the announcement of the proposed Transaction. NioCorp intends to use the proceeds from the proposed Transaction and the contemplated financings to advance its efforts to launch construction of the Elk Creek Project and move it to commercial operation.

08:07 EDT Seagen, Lava Therapeutics announce exclusive LAVA-1223 license agreement - Seagen (SGEN) and Lava Therapeutics (LVTX) announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced preclinical asset that utilizes LAVA's proprietary Gammabody technology to target epidermal growth factor receptor, or EGFR-expressing solid tumors. Under the terms of the agreement, Seagen will receive an exclusive global license for LAVA-1223 and pay LAVA $50M upfront; up to approximately $650M in potential development, regulatory and commercial milestones; and royalties ranging from the single digits to the mid-teens on future sales. The agreement also provides Seagen with the opportunity to exclusively negotiate rights to apply LAVA's proprietary Gammabody platform on up to two additional tumor targets.

08:06 EDT Surrozen publishes study on SZN-413 in preclinical models of DR - Surrozen announced the publication of an article by Surrozen scientists in the journal Translational Vision Science and Technology The results observed with Surrozen's proprietary FZD4-specific agonist, SZN-413, highlight the potential for this novel mechanism of action to simultaneously address the retinal non-perfusion and vascular leakage observed in both oxygen-induced and VEGF-induced preclinical diabetic retinopathy models. Diabetic retinopathy is a microvascular complication of diabetes and a serious public health problem as it is a major cause of vision loss and disability in the middle-aged population. The pathogenesis of DR leads to vascular leakage, which causes diabetic macular edema, and capillary occlusion causing retinal ischemia. These areas of retinal non-perfusion can lead to overproduction of multiple signaling molecules, such as VEGF, that contribute to vascular leakage and pathologic angiogenesis. There are currently multiple anti-VEGF therapies available, however these have not been shown to improve retinal ischemia - leaving a high unmet medical need for new mechanisms of action that have the potential to achieve retinal reperfusion and can reduce the production of factors contributing to vascular leakage and pathologic neovascularization. SZN-413, a bi-specific antibody that targets FZD4 and LRP5, induced Wnt signaling and upregulated blood-retinal barrier gene expression in retinal endothelial cells. FZD4-mediated Wnt signaling is known to play a critical role in retinal vascular development and vessel barrier function in humans and rodent models. The results presented in this paper confirmed that FZD4 and LRP5 are the most abundant and relatively specific receptors expressed in the retinal ECs and SZN-413 induced tight junction proteins in retinal vascular ECs. In a preclinical oxygen-induced retinopathy model, intravitreal injections of SZN-413 significantly reduced avascular area size compared to the positive control, aflibercept. In addition, SZN-413 significantly reduced the pathologic neovascularization area size compared to vehicle and comparable to the positive control. In a VEGF-induced vascular leakage model, SZN-413 reduced retinal vascular leakage from baseline by approximately 80%.

08:05 EDT Seagen, Lava Therapeutics enter worldwide license agreement for LAVA-1223 - Seagen Inc. (SGEN) and LAVA Therapeutics N.V. (LVTX) announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced preclinical asset that utilizes LAVA's proprietary Gammabody technology to target epidermal growth factor receptor-expressing solid tumors. Under the terms of the agreement, Seagen will receive an exclusive global license for LAVA-1223 and pay LAVA $50M upfront; up to approximately $650M in potential development, regulatory and commercial milestones; and royalties ranging from the single digits to the mid-teens on future sales. The agreement also provides Seagen with the opportunity to exclusively negotiate rights to apply LAVA's proprietary Gammabody platform on up to two additional tumor targets. LAVA-1223 employs a targeted approach that is designed to amplify natural tumor recognition by directing gamma delta T cells to the EGFR+ tumor to kill target cells and trigger immune activation while minimizing impact to normal antigen-expressing tissue. Activating the adaptive immune system with this approach has the potential to provide durable immune responses with the possibility of enhancing patient survival.

08:03 EDT Creative Medical announces peer reviewed publication for StemSpine study - Creative Medical Technology announced the peer reviewed publication of positive, two-year follow-up data for the Company's StemSpine study, showing significant efficacy of the StemSpine procedure for treating chronic lower back pain without any serious adverse effects reported. The StemSpine publication demonstrates the clinical use of the patented procedure that utilizes a patient's own bone marrow aspirate for the treatment of chronic lower back pain. There were no safety related concerns at up to two years follow-up. The StemSpine procedure resulted in an efficacy rate of 87% in the treated patients in terms of decreased pain and increased mobility. "The positive two-year data from our StemSpine study is very encouraging and may help alleviate the current opioid crisis related to prescription medication abuse for chronic lower back pain," said Timothy Warbington, President and CEO of the Company. "To our knowledge, this is the first demonstration of the clinical efficacy of injecting bone marrow aspirate into areas surrounding the disc, which may repair, remodel and improve the blood supply around the disc and lower back area. We believe StemSpine represents an attractive non-surgical option for many of the millions of Americans who suffer from chronic lower back pain and look forward to further translation."

07:41 EDT Monarch Mining files technical report for Croinor Gold project - MONARCH MINING CORPORATION announces that it has filed on SEDAR a National Instrument 43-101 technical report for its Croinor Gold project. Monarch published a press release on August 11, 2022, which summarized the assumptions and key results contained in the technical report. There are no material differences between the assumptions and estimates contained in Monarch's press release dated August 11, 2022, pertaining to this property, from those contained in the technical report that was filed today.

07:39 EDT Fennec announces second closing of $20M investment from Petrichor - Fennec Pharmaceuticals completed the second closing of $20M of senior secured promissory notes under our previously announced investment agreement with Petrichor Healthcare Capital Management. Under the terms of the original investment agreement, the second closing of $20M was to be funded upon the U.S. Food and Drug Administration approval of PEDMARK by September 30, 2022 and satisfaction of other closing conditions. On September 20, 2022, the FDA approved the Company's New Drug Application for PEDMARK to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. Further, Fennec upon mutual agreement with Petrichor, may draw up to $20M of additional financing under the investment agreement.

07:38 EDT The Real Brokerage to acquire LemonBrew Lending for $1.3M - The Real Brokerage announced that it signed an agreement to acquire LemonBrew Lending . The acquisition marks the next pivotal step in executing Real's strategy of developing a seamless end-to-end home buying experience. LemonBrew Lending is a tech-enabled home loan platform, licensed to provide a full suite of mortgage services across 20 states in the U.S. including Texas, California, and Florida. The company currently operates as a mortgage brokerage, serving as an intermediary between borrowers and lenders. Additionally, LemonBrew Lending is licensed as a lender in certain states, positioning Real with the option to expand its mortgage platform as long-term strategic needs for the business evolve. As part of the acquisition, Chief Executive Officer of LemonBrew Lending, Samir Dedhia, along with 25 other employees will be joining the team at Real. Pursuant to the terms of a share purchase agreement dated September 23 between Real, LemonBrew Lending and LemonBrew Technologies , the Company will acquire 100% of the issued and outstanding equity interests of LemonBrew Lending from the Seller for an aggregate purchase price of $1,250,000. The purchase price will be satisfied by cash in the amount of $800,000 and the issuance of such number of common shares of Real equal to the product of $450,000 divided by the 5-day volume weighted average trading price of Real's common shares on the NASDAQ immediately prior to the closing of the Acquisition. All dollar figures shown herein are presented in USD. Completion of the Acquisition is subject to a number of further conditions precedent, including, but not limited to: the execution of employment and consulting agreement between Real and certain key officers and employees of LemonBrew Lending; approval of regulatory consents and other customary closing conditions. The Acquisition has been approved by Real's Board of Directors, subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2022.

07:37 EDT Dollar Tree names Michael Creedon, Jr. as COO - Dollar Tree (DLTR) announced an executive leadership addition, as Michael Creedon, Jr. will be joining the organization as COO. Creedon joined Advance Auto Parts (AAP) in December 2013, was executive VP, U.S. Stores since March 2021.

07:36 EDT Purple announces committee to evaluate takeover proposal from Coliseum Capital - Purple Innovation announced that its Board of Directors, in response to an unsolicited and non-binding proposal from Coliseum Capital Management on September 17, 2022 to acquire all of the outstanding capital stock of the Company it does not already own for $4.35 per share in cash, has formed a special committee of independent and disinterested directors and the Special Committee has approved the adoption of a limited-duration shareholder rights plan. Coliseum beneficially owns approximately 45% of Purple's outstanding shares. The Special Committee: The Board formed a Special Committee to take any and all actions necessary to evaluate the Coliseum Proposal and determine the course of action that is in the best interests of all of Purple's shareholders. The Special Committee has not reached any conclusion as to the advisability or feasibility of a potential transaction at this time. The Special Committee is comprised of independent directors Gary DiCamillo, Claudia Hollingsworth, Paul Zepf and Dawn Zier.

07:34 EDT RIV Capital reminds shareholders to vote FOR its board nominees - RIV Capital reminds shareholders that the deadline for voting FOR the Company's board of directors nominees is on September 27, 2022. "We believe that our Board nominees will execute on RIV Capital's strategic vision to become a leader in the industry and capitalize on the lucrative growth of the market in the years ahead," said Mark Sims, Director, President and CEO, RIV Capital. "Under its guidance and stewardship, we believe that the Company will continue to create long-term shareholder value. Without a doubt, the future is bright for RIV Capital."

07:33 EDT W.P. Carey announces ratings upgrade to Baa1 by Moody's Investor Service - W. P. Carey (WPC) announced that Moody's (MCO) Investors Service has upgraded the company's senior unsecured debt and issuer ratings from Baa2 with a positive outlook, to Baa1 with a stable outlook. In the same action, the senior unsecured debt rating of its European affiliate, WPC Eurobond B.V., was upgraded from Baa2 with a positive outlook, to Baa1 with a stable outlook. "Our upgrade by Moody's to Baa1 reflects not only the quality of our portfolio and the strength of our balance sheet, but also our differentiated approach within net lease," said Jason Fox, Chief Executive Officer of W. P. Carey. "We're pleased with this upgrade, which affirms W. P. Carey's sustained positive trajectory since receiving our initial investment grade rating in 2014 - executing on our growth, balance sheet and capital markets strategies."

07:28 EDT Alterity Therapeutics announces presentation from ongoing bioMUSE study - Alterity Therapeutics announced a poster from the ongoing Biomarkers of Progression in Multiple System Atrophy, bioMUSE, natural history study was presented at the International Congress of Parkinson's Disease and Movement Disorders. The presentation correlates data from wearable sensors with clinical assessments of motor function in individuals with Multiple System Atrophy, MSA. MSA is a rapidly progressive parkinsonian disorder that results in slowed movements, lack of coordination and difficulty with walking and balance that predisposes to falls. The poster, entitled Wearable Sensors for Quantitative Motor Assessments in Multiple System Atrophy, describes 12 participants from the ongoing bioMUSE study who wore sensors for up to one year to characterize their motor disability in an outpatient setting. In the study, sensor parameters strongly correlated with clinical scales of motor impairment that were largely driven by changes in gait stability. Investigators concluded that step count and walking time are sensitive measures of disease progression in early MSA. David Stamler, M.D., Chief Executive Officer, Alterity, added, "We are very encouraged by these findings as they validate the use of wearable sensors in our ongoing ATH434 Phase 2 clinical trial in MSA. We are using these sensors in study participants to evaluate motor performance in a real-world setting. Progressive decline in motor function represents an important source of disability in MSA so it is important to have tools to measure it with precision. The data presented demonstrate that we can quantify activity levels of participants to support the outcome of the study."

07:19 EDT Hammerhead, DCRD announce C$1.39B Business Combination - Hammerhead Resources and Decarbonization Plus Acquisition Corporation IV (DCRD), a special purpose acquisition company, announced that they have entered into a definitive agreement for a business combination that values Hammerhead at C$1.39B. Upon closing of the transaction, the combined company is expected to be listed on the Nasdaq Capital Market and trade under the ticker symbol "HHRS". Closing of the transaction is expected to occur in Q1 2023. The combined company will continue to be managed by Hammerhead's current executive team, led by CEO Scott Sobie. "We are extraordinarily proud of the company we have built since inception over a decade ago," said Scott Sobie. "Not only does Hammerhead stand poised to harvest what we consider to be among the most attractive rates of return well locations in Western Canada, but Hammerhead's current emissions profile is already advantaged through its investment of over C$400 million in modern, technically optimized facilities that are being utilized across its properties. We believe an energy transformation is underway where conventional energy and power sources will continue to play an important role in the world energy mix for some time to come. The current global profile of both energy security and resource intermittency are demonstrating the need for continued reliance on conventional sources. We believe the energy industry has an emissions challenge, and we aim to be a leader in redefining public expectations around how companies like ours can contribute to the advancement of global net zero goals." Transaction Details: The transaction is anticipated to generate gross proceeds of approximately $320M, assuming minimal redemptions. The funds will be used to accelerate Hammerhead's CCS program. The pre-money enterprise value of the combined company is C$1,390M at a price of $10 per share. In the event of high redemptions by DCRD's public shareholders, and assuming Hammerhead's planning price deck prevails, Hammerhead would still expect to execute on the CCS program, but at a slower pace. Governance: Hammerhead is currently majority-owned and controlled by affiliates of Riverstone Holdings. The board of directors of DCRD created a Special Committee comprised solely of directors not affiliated with Riverstone to review and approve the transaction and to make a recommendation to the board of directors of DCRD. The DCRD Special Committee engaged Kroll, LLC, operating through its Duff & Phelps Options Practice, to provide a fairness opinion to the DCRD Special Committee and Maples Group as its independent legal counsel for the transaction. The transaction was unanimously recommended and approved by the Special Committees and boards of directors of both Hammerhead and DCRD. It remains subject to the approval of DCRD's and Hammerhead's shareholders and the satisfaction or waiver of other customary conditions. Upon closing, the combined company is expected to feature a seven-person board of directors.

07:12 EDT Schneider Electric delivers new data center cooling infrastructure for UCD - Schneider Electric has worked together with its Elite Partners, Total Power Solutions, to design and deliver a new, high efficiency cooling system to help reduce the PUE of University College Dublin's, UCD, main production data centre. UCD's data centre was originally designed to accommodate high performance computing, HPC, clusters and provides a platform for research at its university campus. As part of a new strategic development plan to free up space at its central Dublin location, the IT services department made the decision to revise and revitalise its data centre cooling architecture to make the facility more energy and space efficient, as well as more resilient and scalable. In response to a public tender, Total Power Solutions, experts in power and cooling infrastructure design and installation, worked with Schneider Electric to secure the contract with a bid to replace the existing data centre cooling system with a Uniflair InRow Direct Expansion solution.

07:10 EDT Lumina Gold announces results from ongoing study at its Cangrejos Project - Lumina Gold announces the remaining results from the 2021-2022 drilling campaign in support of the ongoing Prefeasibility Study at its Cangrejos Project in Ecuador. Marshall Koval, President and CEO commented: "Receiving the final assays from Lumina's 36,000 metre PFS drill campaign allows resource estimation work to commence, which is a critical path item for completion of the PFS. The drill results continue to demonstrate the exceptional continuity of grade at Cangrejos and Gran Bestia and are in line with expectations from previous drilling. The newly drilled step-out areas are expected to add to existing Inferred and Indicated resources and the inclusion of the northwest ridge extension at Gran Bestia may lower the stripping ratio at the mine planning stage of the PFS study."

07:08 EDT Metro Ontario to stock Else Nutrition's full product range - ELSE NUTRITION HOLDINGS announces that it will be rolling out all Canadian SKUs through a partnership with Metro Ontario Inc at Metro locations. Else's Plant-Based Nutrition products for Babies, Toddlers, and Kids will be available on the shelf for purchase in late October at Metro stores across Ontario. With 130 locations in Ontario, the partnership provides Else Nutrition with critical access to health-minded parents seeking plant-based and non-GMO nutritional alternatives for their children.

07:07 EDT Prospect Capital announces results of cash tender offer for Senior Notes - Prospect Capital announced the results of its previously announced cash tender offer to purchase any and all of the outstanding notes listed below. The Tender Offer was made pursuant to an Offer to Purchase dated September 19, 2022, which set forth the terms and conditions of the Tender Offer. As of the previously announced expiration time of 5:00 p.m., New York City time, on September 23, 2022, according to information provided by D.F. King & Co., Inc., the information and tender agent for the Tender Offer, a total of $347,000 aggregate principal amount of Notes had been validly tendered and not validly withdrawn in the Tender Offer. Withdrawal rights for the Notes expired at 5:00 p.m., New York City time, on September 23, 2022. The consideration to be paid for the Eligible Notes is $980.00 for each $1,000 principal amount of Eligible Notes, plus accrued and unpaid interest on the Eligible Notes, if any, from the applicable last interest payment date up to, but not including, the settlement date, which date is expected to be September 28, 2022.

07:06 EDT Coty expands partnership with Cruelty Free International - Coty, one of the world's largest beauty companies with an iconic portfolio of brands, extends its strategic partnership with Cruelty Free International, the leading global organisation working to end animal testing. Coty powerhouse brands Rimmel, Manhattan, and Risque are now approved under the Cruelty Free International Leaping Bunny Programme, joining Coty brand, COVERGIRL, which was approved in 2018. Coty Chief Brands Officer, Consumer Beauty Stefano Curti, comments, "At Coty, we are committed to ending animal testing in the beauty industry. We know consumers expect and search for brands which share their values; they want accessible, kind and cruelty free beauty that works. Rimmel, Manhattan, and Risque have long stood for a better and more kind beauty for all, and for them to have been awarded Leaping Bunny approval is a landmark achievement. Alongside COVERGIRL, Coty is proud to now have four brands approved under the Leaping Bunny Programme."

07:05 EDT Anebulo announces data from ANEB-001 study as a treatment for ACI - Anebulo Pharmaceuticals announced positive interim data from the first two cohorts of Part B of its ongoing Phase 2 clinical trial evaluating ANEB-001 as a treatment for ACI. These new Part B data showed that 10mg of ANEB-001 reversed key symptoms of ACI, comparing favorably to our Part A data showing similar effects with 50mg and 100mg. The 10mg data is even more impressive considering we doubled the THC challenge to 21mg in that cohort," said Simon Allen, Chief Executive Officer of Anebulo. "Using lower doses of ANEB-001 to reduce ACI symptoms should allow us to optimize tolerability, while providing an even more favorable cost of goods if ANEB-001 is approved. We are currently exploring the effects of delayed dosing to better understand real-world conditions. In this circumstance, we challenge subjects with THC one hour before administering ANEB-001. With no FDA approved therapeutic, ACI often requires lengthy emergency department stays with expensive follow-on interventions for neuropsychiatric complications such as anxiety and acute psychosis. We believe ANEB-001 will play a critical role in reducing the burden of ACI for the patient and the healthcare system."

07:04 EDT Kaixin Auto enters binding acquisition term sheet with Morning Star - Kaixin Auto announces that it has signed a binding acquisition term sheet with Wuxi Morning Star Technology Co., who manufactures and operates the POCCO EVs. According to the term sheet, Kaixin intends to acquire 100% equity of Morning Star through new share issuance and makes it a wholly owned subsidiary. Morning Star acquired 100% equity of Henan Yujie Time Limited earlier this year, and is actively promoting the strategic re-positioning and re-branding of the company from "a leading mini multi-purpose electric passenger vehicle producer" to "a pioneer in smart mini new energy vehicles." The POCCO EV business under Morning Star produces the MeiMei and DuoDuo brands of mini electric passenger vehicles. The total sales volume has exceeded 40,000 units since its start of operations in June 2021, which makes POCCO EV among the top 6 producers of mini electric vehicles in China. Morning Star possesses core technologies in electric vehicles manufacturing and owns 100 patents, including the battery, motor and control systems, intelligent interconnection and autonomous driving, battery integration and quick change, battery range extension, and fuel cells. The core management team of Morning Star collectively have more than 20 years of experience in automobile and new energy vehicle business management. Kaixin and Morning Star have reached consensus to advance the M&A transaction in a fast track. They expect to sign the definitive acquisition SPA by end of October and have the acquisition transaction completed by end of the year.

07:03 EDT Janus International Group appoints Elliot Kahler as general counsel - Janus International Group announced the appointment of Elliot Kahler to general counsel. Kahler joined Janus as Corporate Counsel in 2018 and was integral in establishing the company's in-house legal department. In his new role as general counsel, Elliot will continue to lead and manage Janus's in-house legal team and oversee all matters relating to corporate governance and other relevant federal and state securities laws, regulations, and rules. He will continue reporting to Ramey Jackson, CEO of Janus.

07:03 EDT Codex DNA to showcase BioXp 9600 system at World of Technology & Science - Codex DNA will showcase its recently released BioXp 9600 system at the World of Technology & Science conference which begins tomorrow in Utrecht, Netherlands. The BioXp 9600 system will be showcased at the Codex DNA booth in Hall 7 number A091. The BioXp 9600 system, a next-generation high throughput platform that builds biology overnight and at the push of a button empowering scientists to accelerate discovery of new vaccines and biologics, is the third release on the powerful and versatile BioXp platform.

07:00 EDT Palantir awarded $95.9M contract to support Homeland Security Investigations - Palantir Technologies announced that the Department of Homeland Security renewed its contract to support Homeland Security Investigations with Investigative Case Management software. The contract is worth $95.9M over a five-year period.

06:58 EDT Aecom appoints Dawn MacDonald as global offshore wind sector lead - AECOM announced it has appointed Dawn MacDonald as its Global Offshore Wind Market Sector Lead. In this role, Ms. MacDonald will work across the globe to advance an integrated offshore wind offering that leverages AECOM's leading environmental and port infrastructure expertise to new and existing clients.MacDonald brings a portfolio of offshore wind experience, having overseen development, construction, and operations projects as part of the Maple Power joint venture in Europe.

06:52 EDT Wabash announces amendment to asset-backed lending facility - Wabash announced an amendment to its asset-backed lending facility, increasing the total credit facility to $350M and creating additional liquidity of up to $125M. The increased liquidity is anticipated to be used to accelerate the availability of Wabash's Trailers as a Service offering. Upon closing of this amended credit agreement and based on current eligible assets, liquidity increased approximately $100M. The agreement extends the scheduled maturity to September 23, 2027, and includes options to increase facility size up to $525M, subject to certain terms and conditions including approval from lenders.

06:47 EDT Pfizer, BioNTech submit EUA application for bivalent vaccine booster in children - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced they have completed a submission to the U.S. Food and Drug Administration requesting Emergency Use Authorization of a 10-microgram booster dose of the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. The request for Emergency Use Authorization of the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is supported by safety and immunogenicity data from the companies' bivalent Omicron BA.1-adapted vaccine, non-clinical and manufacturing data from the companies' 10-microgram bivalent Omicron BA.4/BA.5-adapted vaccine, and pre-clinical data from the companies' Omicron BA.4/BA.5-adapted vaccine in their decision. An application to extend the Omicron BA.4/BA.5-adapted bivalent vaccine marketing authorization to include children ages 5 through 11 years will be submitted to the European Medicines Agency in the coming days. The companies have also initiated a Phase 1/2/3 study NCT05543616 to evaluate the safety, tolerability, and immunogenicity of different doses and dosing regimens of the companies' Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 6 months through 11 years of age. This pediatric study is consistent with regulatory guidance and follows a previous Phase 1/2/3 trial involving these age groups that demonstrated the original Pfizer-BioNTech COVID-19 Vaccine is well-tolerated and offers a high level of protection against COVID-19, measured at a time when the Omicron BA.2 strain was highly prevalent. The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech's proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder for BNT162b2 in the United States, the European Union, the United Kingdom, Canada and other countries, and the holder of emergency use authorizations or equivalents in the United States and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.

06:37 EDT Pure Gold Mining files independent technical report for PureGold Mine - Pure Gold Mining announced that following the release of an updated Mineral Resource Estimate on August 10th 2022, the Company has filed a National Instrument 43-101 Technical Report entitled "Independent NI 43-101 Technical Report and Updated Mineral Resource Estimate for the PureGold Mine, Canada", prepared by SRK Consulting, dated September 23rd, 2022, with an effective date of December 31st, 2021. 2022 Mineral Resource Estimate Highlights: The PureGold Mine MRE includes: 1.65 million ounces of gold at 7.4 grams per tonne within 6.9 million tonnes in the Indicated Mineral Resource category, and 0.37 million ounces of gold at 6.3 g/t within 1.8 million tonnes in the Inferred Mineral Resource category. The updated MRE will form the basis of a new Pre-Feasibility Study and updated Life of Mine plan, which is being led by SRK and expected to be released in the fourth quarter of 2022. This updated PFS will incorporate several ongoing trade-off studies and will identify the best value-maximizing operational path forward for the Company.

06:35 EDT Magellan Healthcare to host webinar addressing depression - Magellan Healthcare announced resources addressing depression in adults and youth in support of National Depression and Mental Health Awareness and Screening Month in October. On Tuesday, October 25th from 2:00 pm-3:00 pm ET, join Magellan Healthcare for the webinar, "Depression is real. Recovery is possible," featuring a Magellan employee who has lived with depression since childhood and will share her inspirational story of recovery. Hear from our doctors who will share their knowledge and professional experience in addressing depression in adults and youth. Presenters will be Amanda Grace Krier, AAS, CPS, Magellan Healthcare youth support coordinator; Jamie Hanna, MD, Magellan Healthcare medical director; and Rakel Beall-Wilkins, MD, MPH, Magellan Healthcare medical director.

06:34 EDT Planet 13 Holdings receives approvals for Nevada cultivation expansion - Planet 13 Holdings announced the receipt of the necessary approvals to operate its 22,000 square foot Nevada cultivation expansion and the planting of the first harvest from new grow rooms ahead of the previously forecasted timeline of Q4 2022.

06:33 EDT Denison Mines completes commissioning of lixiviant injection system - Denison Mines announced the completion of commissioning of the lixiviant injection system for the Phoenix in-situ recovery, or ISR, Feasibility Field Test, or FFT, at the company's 95% owned Wheeler River project. The lixiviant injection system is the critical operating component necessary to support the leaching phase of the FFT.

06:20 EDT Meridian Mining announces mineral resource estimate for Cabacal Deposit - Meridian Mining UK announced its maiden Mineral Resource estimate for the Cabacal copper-gold-silver VMS Deposit "Cabacal" in Mato Grosso, Brazil. The Mineral Resource estimate was provided by specialist group, H&S Consultants Pty and comprises Indicated Resources of 52.9 Mt @ 0.6g/t Au, 0.3% Cu & 1.4g/t Ag plus Inferred Resources of 10.3Mt @ 0.7g/t Au, 0.2% Cu and 1.1g/t Ag at a 0.3g/t AuEq cut-off grade. Significantly, the resource is near-surface, and extends over 1.9km with a prominent high-grade shallow gold zone in the Cabacal Northwest Extension. Ongoing drilling on the margins of the resource has intercepted strong zones of copper-gold mineralization; further drill results are pending. Meridian announces a new Mineral Resource Estimate for the Cabacal Cu-Au-Ag deposit.; Indicated resources of 52.9Mt @ 0.6g/t Au, 0.3% Cu and 1.4g/t Ag; 1.1M ounces gold, 168.0 Kt of copper and 2.4M ounces of silver; Inferred Resources of 10.3Mt @ 0.7g/t Au, 0.2% Cu & 1.1g/t Ag; 0.2M ounces gold, 24.5 Kt of copper and 0.4M ounces of silver; Cabacal's Au-Cu-Ag resource extends over 1.9km in length and remains open; Ongoing drilling has encountered multiple zones of Cu-Au-Ag mineralization; Extensions along strike to the northwest, down-dip and up-dip remain under evaluation; High grade Cabacal Northwest Extension to be initial focus for future mine schedule studies; Cabacal's metallurgical results used to estimate recovery for metals; Future results from Cabacal's "resource expansion drill program" to be included in a 2023 Mineral Resource update. Gilbert Clark Executive Chairman and Dr Adrian McArthur, CEO and President, jointly comment: "Today's Mineral Resource publication confirms Meridian's Cabacal copper-gold-silver project to be one of the most significant resources still held by a junior within a large tenement package covering the hosting VMS belt. Meridian's technical team has done a remarkable job in delivering this resource in only 18 months since the start of drilling. The metallurgical work completed by the Company demonstrates that the Indicated Resource category 1.1 million ounces of gold, 168 thousand tonnes of copper and 2.4 million ounces of silver are amenable to processing through conventional flotation and gravity processes. The resource is located at shallow depths and shows excellent potential for a long life stand-alone open-pit within the upside of the greater Cabacal VMS belt. Ongoing drilling has been very positive, and we look forward to Cabacal's future development and growth."

06:11 EDT Krispy Kreme offers free coffee on National Coffee Day - Krispy Kreme once again will sweeten National Coffee Day with a free brewed coffee for all guests this Thursday, Sept. 29. Krispy Kreme Rewards members get an even sweeter deal - a free doughnut of choice to accompany their free coffee. The free offers are available for carry-out and via drive-thru at participating shops across the U.S., no purchase necessary.

06:08 EDT Microvast announces outcome of XFC project - Microvast Holdings announced the outcome of its extreme fast charge project, funded in part by the US Department of Energy's Office of Energy Efficiency & Renewable Energy - Vehicle Technologies Office. The stated goal of this XFC project was to deliver a lithium-ion automotive format pouch cell for electric vehicles capable of exceeding 500 cycles while charging in less than 10 minutes and (2) delivering at start of life greater than 180 Wh/kg of stored energy after 10-minute charge, greatly improving the accessibility and driving mobility for EVs. During this project, Microvast worked with Argonne National Laboratory to provide advanced cell system characterization and BMW provided OEM charging considerations and general feedback. Microvast delivered a 35 Ah, 240 Wh/kg pouch cell using layered metal oxide and graphite chemistry to the US DOE National Lab for independent testing. The XFC cells were tested using a 10-minute fast charge and 1C discharge at 30degreesC. Under these conditions, the XFC cells delivered over 1,700 cycles before reaching end of life, which exceeded the stated goal of the life cycle of the project's prototype cells by 3.4X.

06:05 EDT Vertical Aerospace announces take off of the VX4 eVTOL - Vertical Aerospace saw its VX4 eVTOL aircraft take off from the ground for the very first time over the weekend. The company said, "The moment marked a significant milestone as Vertical continues to progress successfully through its intensive flight test programme. The programme is expected to continue for several months, completing different stages which will involve reaching higher altitudes and speeds and demonstrating the transition from vertical to horizontal forward flight. Engineers and flight technicians watched on as Chief Test Pilot, Justin Paines, took to the controls for the aircraft's maiden take-off which saw the eight sets of aerodynamic propellers lift the aircraft from the ground at hover-thrust, while tethered to the ground for safety...The permit and the positive results of these early tests allow the teams at Vertical to progress confidently on their mission to certify the VX4 by 2025. It is hoped the aircraft will carry a pilot and four passengers and is expected to have a range of up to 100 miles with the ability to cruise at speeds of around 150 miles per hour, with a top speed of 200 miles per hour." The company has already received more than 1,400 conditional pre-orders from some of the world's leading airlines, operators, lessors and tourist groups including Virgin Atlantic, American Airlines, Japan Airlines and Air Asia and recently announced that American Airlines has conditionally committed to make a pre-payment for its first 50 deliveries of the VX4.

05:24 EDT Chevron, Mitsui Oil Exploration announce joint collaboration agreement in Japan - Chevron and Mitsui Oil Exploration announced the signing of a joint collaboration agreement to explore the technical and commercial feasibility of advanced geothermal power generation in Japan. Building on Chevron and Moeco's long-standing relationship, the new collaboration will study geothermal resource potential across Japan and will evaluate the effectiveness of Advanced Closed Loop, or ACL, technology for a future joint pilot project in Japan. Both companies may also assess potential collaboration for advanced geothermal technology opportunities using ACL globally. ACL can potentially enable access to geothermal resources at a wider range of temperatures and geologies through the application of alternative technology above and below the surface.

05:20 EDT Amazon unveils Prime Early Access Sale exclusive to Prime members - Amazon unveiled Prime Early Access Sale, a new two-day global shopping event exclusive to Prime members. The event begins October 11 at 12 a.m. PDT and runs through October 12 in 15 countries: Austria, Canada, China, France, Germany, Italy, Luxembourg, the Netherlands, Poland, Portugal, Spain, Sweden, Turkey, the UK, and the U.S. Prime Early Access Sale gives members a chance to kick off the holiday shopping season early with hundreds of thousands of deals. As part of the new deals event, Amazon is introducing a Top 100 list of some of the season's most popular and giftable items. New deals from the list will drop throughout the event, offering savings across all top categories, including electronics, fashion, home, kitchen, pets, toys, and Amazon devices.

05:14 EDT Vaalco Energy receives approval for Venus - Block P POD - Vaalco Energy announced that the Government of Equatorial Guinea has approved the Venus - Block P Plan of Development, or POD. Vaalco Energy has an 80% participation interest in the project and is the operator. Upon the execution of final documents, Vaalco Energy will proceed directly to project execution which targets first oil in 2026 and adds 23.1M barrels of oil of 2P CPR gross reserves, and 18.5 MMBO of 2P CPR Working Interest reserves. On July 15, Vaalco, on behalf of itself and Guinea Ecuatorial de Petroleos, submitted to the EG MMH a plan of development for the Venus development in Block P. The other Block P joint venture owner, Atlas Petroleum International, opted not to participate in the POD. On September 16, the Equatorial Guinea Minister approved Vaalco POD. As a result, Vaalco will hold an 80% working interest in the Venus development in Block P and GEPetrol will hold a 20% carried interest. The Block P PSC provides for a development and production period of 25 years from the date of approval of the POD.

05:11 EDT Paysafe announces entry into Kansas online sports-betting market - Paysafe (PSFE) announced its entry into the new Kansas online sports-betting market. The move sees Paysafe supporting multiple online sportsbooks in the state with players' credit and debit card deposits plus ACH payments, while its marketing technology and services provider Income Access is powering the affiliate marketing programs of several Kansas iGaming brands. With Kansas going live this month with online and retail sports-betting in time for the 2022 NFL season's kickoff, the market becomes the 23rd U.S. state or jurisdiction where Paysafe has a presence supporting operators with payments. In Kansas, Caesars (CZR), DraftKings (DKNG), and PointsBet (PBTHF), have all extended their longstanding payments partnerships with Paysafe.

05:06 EDT Ideanomics to establish in-house design capabilities - Ideanomics is establishing in-house design capabilities. Ideanomics Design will strengthen its balance sheet by embedding a more cost-effective, efficient, and standardized design process across the organization. Ideanomics Design is also introducing a modular design approach to increase efficiency and flexibility across different product categories. This will enable Ideanomics to deliver manufacturing that allows customers to track and customize their products while they are being built. While primarily focused on in-house work, Ideanomics Design will also generate revenue by providing consulting services to third parties.